Bromazolam Blister – 10x 2.5mg

A. Introduction

Bromazolam Blister 10x 2.5mg is a premium laboratory-grade research chemical containing triazolobenzodiazepine analog, designed for scientific institutions and analytical laboratories investigating novel benzodiazepine receptor ligands. This high-purity blister format provides researchers with consistent 2.5mg units for method validation, structural analysis, and multi-point calibration curves in controlled settings.

B. Scientific Overview

Bromazolam belongs to the triazolobenzodiazepine class structurally related to alprazolam, characterized by its fused triazolo-benzodiazepine scaffold with 8-bromo substitution suitable for analytical profiling. In research contexts, it functions as an analytical reference for studying chromatographic behavior, mass spectrometry fragmentation patterns, and spectroscopic signatures of high-affinity benzodiazepine analogs with binding affinities at α1 (Ki=2.81 nM), α2 (Ki=0.69 nM), and α5 (Ki=0.62 nM) subunits.

Laboratory investigations focus on its chemical properties, including uniform dissolution characteristics, solubility profiles in organic solvents like ethanol/DMSO, and stability under analytical conditions, without reference to biological interactions.

C. Product Specifications

• Form: Blister-packed tablets containing 2.5mg bromazolam per unit (10 tablets per blister)

• Label per unit: 2.5mg analytical portions in tamper-evident blister packaging

• Synonym: 8-Bromo-1-methyl-6-phenyl-4H-benzo[f]triazolo[4,3-a]diazepine

• CAS Number: 71368-21-9

• Molecular Formula: C₁₇H₁₃BrN₄

• Molecular Weight: 353.22 g/mol

• Purity: ≥98% (HPLC, typical batch purity)

• Storage Conditions: Cool, dry place (2-8°C recommended), protected from light/moisture for stability; melting point ~160-162°C

D. Laboratory Use Context

Bromazolam Blister 10x 2.5mg is designated solely for in-vitro analytical research, including reference standard preparation, LC-MS/MS method optimization for triazolobenzodiazepines, forensic toxicology screening, and impurity detection in complex matrices.

Researchers apply it in controlled environments for quantitative analysis, positive ionization studies ([M+H]+), and stability testing via HPLC/UV protocols. The blister format ensures sample integrity for replicate analyses and long-term stability studies across pharmacological concentration ranges.

E. Quality & Testing

Every batch receives comprehensive quality control:

• Certificate of Analysis (COA) with HPLC, MS, NMR identity confirmation and tablet uniformity testing

• Full batch traceability from synthesis through blister packaging and verification

• Third-party laboratory testing for purity, content uniformity, dissolution profile, and residual solvents

• Manufactured under controlled conditions ensuring consistent tablet performance (±2% RSD) and stability

F. Shipping & Handling

Discreet worldwide shipping to verified research laboratories via secure, compliant carriers. Blister packaging provides inherent protection meeting IATA/DOT standards for research chemicals, with full documentation for customs clearance. Tracking provided; buyers confirm jurisdictional import compliance prior to purchase.

G. Compliance Disclaimer

For Research Use Only. Not for human consumption.
This product is supplied strictly as a laboratory reagent for analytical purposes. It is not approved for human, veterinary, diagnostic, or therapeutic applications. No statements imply biological effects beyond in-vitro research contexts.

Qualified researchers and institutions assume full responsibility under local, federal, and international laws. Seller disclaims all liability for non-research use. Consult safety data sheets and institutional protocols before handling.